



PATENT
CBR 3.0-016

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of
Moo-Young

Application No. 09/154,283

Filed: September 16, 1998

For: ANDROGEN AS A MALE
CONTRACEPTIVE AND NON-
CONTRACEPTIVE ANDROGEN
REPLACEMENT

Group Art Unit: 1617

Examiner: Moezie, M.

Date: June 15, 2000

Assistant Commissioner for Patents
Washington, D.C. 20231

REPLY AND AMENDMENT

Sir:

In complete response to the Official Action mailed December 16, 1999, please
amend the above-captioned application as follows.

IN THE CLAIMS


2 Please amend the claims as follows *2*

Sub
cl
B1
1. (Amended) A method of male contraception comprising the step of:
administering to a non-sterile male subject a predetermined amount of an androgen which is
sufficient to render said male subject reversibly sterile for a predetermined period of time and
which provides said male subject with blood levels of LH and FSH of 2.5 IU/L or less and
testosterone of 10 nmol/liter or less and wherein said androgen is substantially the only
sterilizing agent administered to said male subject for the purposes of contraception

2. (Amended) A method of male contraception [comprising] consisting
essentially of the step of: administering to a non-sterile male subject a predetermined amount
of a non-5 α -reducible androgen which is sufficient to render said male subject reversibly
sterile for a predetermined period of time.

3. (Amended) The method of claims 1 or 2 wherein said androgen is MENT [or
MENT Ac] and its pharmaceutically acceptable salts.

I hereby certify that this correspondence is being deposited with
the United States Postal Service with sufficient postage as First
Class mail in an envelope addressed to Assistant Commissioner for
Patents, Washington, D.C. 20231 on June 15, 2000.


(Signature)

Michael H. Teschner